Skip to content

argenx describes itself as reaching patients through immunology innovation, with a culture built on the collective power of the team.

Last updated September 10, 2026

AI crawler reads

2requests

1companies
  • Anthropic2
Profile
2
Controversies
0
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

From this site's server log

Overview

argenx presents itself as an organization focused on immunology innovation, stating that "The science of co-creation drives our quest to engineer life-changing immunology solutions." Its name is explained as coming from the story of the Argonauts, and the company describes an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side. It states that it has a product approved for use in the United States and describes a one-tier board consisting of executive and non-executive directors, with an executive management team responsible for day-to-day operations.

History

argenx states that its name comes from the ancient myth of the Argonauts, described as one of the first stories on record recognizing the power of the team rather than one hero. The company says the Argonauts set out in a small boat on a wide ocean on a mission to find the golden fleece, a seemingly impossible task achieved through the collective effort of the team. argenx also states that it has created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side.

Products and positioning

Reaching Patients Through Immunology Innovation

Recent events

  • Reported

    FDA approves Vyvgart for myasthenia gravis[5]

    The FDA approved Vyvgart for adults with myasthenia gravis who are positive for acetylcholine receptor antibody.

  • Reported

    Janssen affiliate announces end of cusatuzumab collaboration with argenx[6]

    Cilag GmbH International, a Janssen Pharmaceutical Companies of Johnson & Johnson affiliate, announced that it would not continue its collaboration and license agreement with argenx for cusatuzumab. Janssen said it would work with argenx to transition the program back to argenx.

  • Reported

    Pure MHC and argenx announce initial collaboration project[7]

    Pure MHC announced an initial collaboration project with argenx to support a more robust understanding of how antigen presentation changes in the presence of specific therapeutic agents.

Read more

Sources7 sources

Cite this profile: Cite the canonical profile. /brand-wiki/argenx · Editorial policy · How profiles are compiled